FRANKLIN LAKES, N.J.,
April 26, 2017 /PRNewswire/
-- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading
global medical technology company, today announced that it has
non-exclusively licensed its patented stochastic labelling
technology to Roche for multiple commercial applications.
BD's patented stochastic labelling technology incorporating
molecular indexes (known also as UMIs or molecular barcodes),
enables the precise counting of individual biological molecules,
including DNA or RNA, in complex and often volume-limited samples.
BD is developing a suite of products utilizing this technology for
accurate quantitative measurements of mRNA targets from single
cells, enabling researchers to gain greater insights into the
biology of complex and heterogeneous samples.
BD is also working with additional partners to license this
technology and enable the development of novel tools and assays for
the scientific community.
"Stochastic labelling with molecular indexes is a simple, yet
powerful, approach for the accurate quantification of target
molecules in complex biological samples," said Stephen Gunstream, vice president of Genomics at
BD. "This technology enables a range of future products that will
broadly benefit many areas of research and future clinical
applications."
Specific financial terms of the agreement have not been
disclosed.
For additional information, including inquiries regarding
licensing of these technologies, contact BD at +1 650-665-2400.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has nearly 50,000 associates
across 50 countries who work in close collaboration with customers
and partners to help enhance outcomes, lower health care delivery
costs, increase efficiencies, improve health care safety and expand
access to health. For more information on BD, please visit
bd.com.
Contacts:
|
|
|
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
monique_dolecki@bd.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bd-licenses-novel-molecular-indexing-technology-to-roche-300445887.html
SOURCE BD (Becton, Dickinson and Company)